MedPath

Pulpotomy Technique Preserving Vitality of Traumatized Anterior Permanent Immature Teeth

Phase 2
Completed
Conditions
Pulp Exposure, Dental
Interventions
Biological: mineral trioxide aggregate
Biological: Biodentine
Procedure: cervical pulpotomy
Registration Number
NCT03838068
Lead Sponsor
Gihan M Abuelniel ,PhD
Brief Summary

Aim of the study: To compare the clinical and radiographic outcomes of mineral trioxide aggregate (MTA) and Biodentine as vital pulp therapy materials (pulpotomy) preserving the vitality of traumatized immature anterior permanent teeth.

Materials and Methods: fifty vital traumatized immature anterior permanent teeth exposed with symptomatic /asymptomatic pulpitis were included in the study according to inclusion criteria and were equally divided in two groups. Included teeth were randomly assigned to either a control group (MTA 25 teeth) or a test group (Biodentine 25 teeth). After conducting pulpotomy and covering pulp stumps with the MTA and Biodentine, treated teeth received permanent restorations. Blinded clinical and radiographic evaluations were performed at different time intervals (base line immediate postoperative, 6, 12 and 18 months) according to clinical and radiographic criteria of success. Data were recorded and analyzed.

Detailed Description

Informed consent was obtained from all patients prior to treatment, and patients were offered Root canal treatment in case of treatment failure.

Thirty-three patients who were referred to the postgraduate pediatric dentistry department clinic for the management of their traumatized permanent incisors teeth were assessed. Only Patients who had a traumatic incisor tooth with a vital pulp (detected by clinical signs/symptoms) were included.

Incisors were assigned randomly in the two groups. The MTA group was considered the control group while the biodentine was the test group.

All patients who were clinically eligible for enrollment in the study went through screening pre-operative digital periapical radiographic examination to assess the degree of root development/ formation and any dental infections or anomalies that could interfere with the planned treatment.

The main investigator performed all pulpotomies. Local anesthesia was administrated followed by rubber dam isolation, the coronal pulp tissue was excised to the level of the orifice using a diamond bur with water cooling. Hemostasis was achieved by gentle placement of a saline-moistened cotton pellet over amputated pulps for 5-10 min. Pulp stumps were covered with:

In the first group (control group) white mineral trioxide aggregate (MTA) ProRoot® MTA (Dentsply/ Johnson City,TN,USA) was used as the reference material for comparison and was prepared according to the manufacturer's instructions. A 3-mm-thick layer of MTA was placed over the amputated pulps and was gently adapted to the dentinal walls using a wet cotton pellet deep onto the radicular pulp. A self-cure glass ionomer (GC; GC Corporation, Tokyo, Japan) was placed over the pulpotomy agent before final restoration of composite resin (ClearfilTM, Kuraray, New York, USA) was done.

In the second group Calcium silicate-based BiodentineTM (Septodont Ltd., Saint Maur des Fausse´s, France) was mixed according to the manufacturer's instructions, pulpotomy was performed, radicular pulp was covered, and teeth received self-cure glass ionomer prior to final restoration with the same technique as in the first group.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
33
Inclusion Criteria
  • The patient age range 7.5-9 years.
  • Noncontributory medical history
  • Unilateral/ and or bilateral central incisors tooth with complicated trauma (exposure size ≥ 1mm)
  • The tooth should give positive response to cold testing
  • Clinical diagnosis of reversible pulpitis without periapical rarefaction
  • The tooth is restorable, mobility was within normal limits
  • No signs of pulpal necrosis including sinus tract or swelling
Exclusion Criteria
  • Teeth with mature roots
  • Signs and symptoms of irreversible pulpitis
  • Non-restorable teeth
  • Negative response to cold testing, the presence of sinus tract or swelling
  • No pulp exposure
  • Bleeding could not be controlled after full pulpotomy in 6 minutes

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Mineral trioxide aggegateLocal Anesthetics Procainewhite mineral trioxide aggregate (MTA) calcium silicate-based cement
Mineral trioxide aggegatecervical pulpotomywhite mineral trioxide aggregate (MTA) calcium silicate-based cement
Mineral trioxide aggegatemineral trioxide aggregatewhite mineral trioxide aggregate (MTA) calcium silicate-based cement
BiodentineBiodentinecalcium silicate-based cement that consists of tricalcium silicate, dicalcium silicate, calcium carbonate, calcium oxide, zirconium oxide, and CH.
BiodentineLocal Anesthetics Procainecalcium silicate-based cement that consists of tricalcium silicate, dicalcium silicate, calcium carbonate, calcium oxide, zirconium oxide, and CH.
Biodentinecervical pulpotomycalcium silicate-based cement that consists of tricalcium silicate, dicalcium silicate, calcium carbonate, calcium oxide, zirconium oxide, and CH.
Primary Outcome Measures
NameTimeMethod
presence of pain,sensitivity to percussion/ palpation18 months

by asking the patient( questionnaire) (Binary measure) ( Yes or No) where Yes indicates failure of the treatment

presence of mobility18 months

by the back of the mirror( Binary measure) (Yes or No) where Yes indicates clinical failure of the treatment.

Swelling or sinus tract18 months

by visual examination (binary measure)( Yes or No) where Yes indicates clinical failure of the treatment

Secondary Outcome Measures
NameTimeMethod
Stage of root development18 months

by radiographic parallel technique ( four root development stages are assessed E, F,G and H) where E is the worse and H is the best stage.

Presence of radiolucency18 months

by radiographic parallel technique (Binary measure) (Yes or No) where Yes indicates radiographic failure of the treatment.

Trial Locations

Locations (1)

Gihan Abuelniel

🇪🇬

Giza, Egypt

© Copyright 2025. All Rights Reserved by MedPath